Show simple item record

dc.contributor.authorMelero, I
dc.contributor.authorGaudernack, G
dc.contributor.authorGerritsen, W
dc.contributor.authorHuber, C
dc.contributor.authorParmiani, G
dc.contributor.authorScholl, S
dc.contributor.authorThatcher, Nick
dc.contributor.authorWagstaff, J
dc.contributor.authorZielinski, C
dc.contributor.authorFaulkner, I
dc.contributor.authorMellstedt, H
dc.date.accessioned2014-09-04T09:04:47Z
dc.date.available2014-09-04T09:04:47Z
dc.date.issued2014-07-08
dc.identifier.citationTherapeutic vaccines for cancer: an overview of clinical trials. 2014: Nat Rev Clin Oncolen
dc.identifier.issn1759-4782
dc.identifier.pmid25001465
dc.identifier.doi10.1038/nrclinonc.2014.111
dc.identifier.urihttp://hdl.handle.net/10541/325841
dc.description.abstractThe therapeutic potential of host-specific and tumour-specific immune responses is well recognized and, after many years, active immunotherapies directed at inducing or augmenting these responses are entering clinical practice. Antitumour immunization is a complex, multi-component task, and the optimal combinations of antigens, adjuvants, delivery vehicles and routes of administration are not yet identified. Active immunotherapy must also address the immunosuppressive and tolerogenic mechanisms deployed by tumours. This Review provides an overview of new results from clinical studies of therapeutic cancer vaccines directed against tumour-associated antigens and discusses their implications for the use of active immunotherapy.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Nature reviews. Clinical oncologyen
dc.titleTherapeutic vaccines for cancer: an overview of clinical trials.en
dc.typeArticleen
dc.contributor.departmentCentro de Investigacion Medica Aplicada (CIMA) and Clinica Universitaria (CUN), Universidad de Navarra, Spainen
dc.identifier.journalNature Reviews Clinical Oncologyen
html.description.abstractThe therapeutic potential of host-specific and tumour-specific immune responses is well recognized and, after many years, active immunotherapies directed at inducing or augmenting these responses are entering clinical practice. Antitumour immunization is a complex, multi-component task, and the optimal combinations of antigens, adjuvants, delivery vehicles and routes of administration are not yet identified. Active immunotherapy must also address the immunosuppressive and tolerogenic mechanisms deployed by tumours. This Review provides an overview of new results from clinical studies of therapeutic cancer vaccines directed against tumour-associated antigens and discusses their implications for the use of active immunotherapy.


This item appears in the following Collection(s)

Show simple item record